Stomatology ›› 2023, Vol. 43 ›› Issue (12): 1106-1111.doi: 10.13591/j.cnki.kqyx.2023.12.010
• Summary • Previous Articles Next Articles
Revised:
2023-04-03
Online:
2023-12-28
Published:
2023-12-28
Contact:
JIANG Lu
E-mail:jianglu@scu.edu.cn
CLC Number:
ZHANG Tianyu,JIANG Lu. Research progress of IgG4-related disease in oral cavity[J]. Stomatology, 2023, 43(12): 1106-1111.
[1] |
Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976):1460-1471.
doi: 10.1016/S0140-6736(14)60720-0 pmid: 25481618 |
[2] |
Brito-Zerón P, Ramos-Casals M, Bosch X, et al. The clinical spectrum of IgG4-related disease[J]. Autoimmun Rev, 2014, 13(12):1203-1210.
doi: 10.1016/j.autrev.2014.08.013 pmid: 25151972 |
[3] | Uchida K, Masamune A, Shimosegawa T, et al. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009[J]. Int J Rheumatol, 2012, 2012:358371. |
[4] |
Lanzillotta M, Fernàndez-Codina A, Culver E, et al. Emerging therapy options for IgG4-related disease[J]. Expert Rev Clin Immunol, 2021, 17(5):471-483.
doi: 10.1080/1744666X.2021.1902310 |
[5] |
Kawa S, Ota M, Yoshizawa K, et al. HLA DRB1*0405-DQB1*0401 haplotype is associated with autoimmune pancreatitis in the Japanese population[J]. Gastroenterology, 2002, 122(5):1264-1269.
doi: 10.1053/gast.2002.33022 |
[6] |
Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2019, 143(2):736-745.e6.
doi: S0091-6749(18)30768-1 pmid: 29852256 |
[7] | Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis[J]. Sci Transl Med, 2018, 10(453):eaaq0997. |
[8] |
Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease[J]. Gut, 2018, 67(4):728-735.
doi: 10.1136/gutjnl-2017-314548 pmid: 28765476 |
[9] |
Sasaki T, Akiyama M, Kaneko Y, et al. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease[J]. Clin Exp Rheumatol, 2018, 36 Suppl 112(3):186-189.
pmid: 29846165 |
[10] |
Tang JG, Cai SZ, Ye C, et al. Biomarkers in IgG4-related disease:A systematic review[J]. Semin Arthritis Rheum, 2020, 50(2):354-359.
doi: 10.1016/j.semarthrit.2019.06.018 |
[11] |
Della-Torre E, Rigamonti E, Perugino C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2020, 145(3):968-981.e14.
doi: S0091-6749(19)30936-4 pmid: 31319101 |
[12] |
Kubo S, Nakayamada S, Zhao JD, et al. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease[J]. Rheumatology (Oxford), 2018, 57(3):514-524.
doi: 10.1093/rheumatology/kex455 pmid: 29253269 |
[13] |
Tsuboi H, Matsuo N, Iizuka M, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease[J]. Arthritis Res Ther, 2012, 14(4):R171.
doi: 10.1186/ar3924 |
[14] |
Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator- and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis[J]. Pancreas, 2011, 40(7):1120-1130.
doi: 10.1097/MPA.0b013e31821fc796 |
[15] |
Perugino CA, Kaneko N, Maehara T, et al. CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease[J]. J Allergy Clin Immunol, 2021, 147(1):368-382.
doi: 10.1016/j.jaci.2020.05.022 pmid: 32485263 |
[16] |
Perugino CA, Stone JH. IgG4-related disease:An update on pathophysiology and implications for clinical care[J]. Nat Rev Rheumatol, 2020, 16(12):702-714.
doi: 10.1038/s41584-020-0500-7 |
[17] |
Ji ZF, Chen RY, Cui XM, et al. In vitro IL-6/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease[J]. Front Immunol, 2020, 11:1272.
doi: 10.3389/fimmu.2020.01272 pmid: 32733444 |
[18] |
Yamada K, Yamamoto M, Saeki T, et al. New clues to the nature of immunoglobulin G4-related disease:A retrospective Japanese multicenter study of baseline clinical features of 334 cases[J]. Arthritis Res Ther, 2017, 19(1):262.
doi: 10.1186/s13075-017-1467-x |
[19] |
Inoue D, Yoshida K, Yoneda N, et al. IgG4-related disease:Dataset of 235 consecutive patients[J]. Medicine, 2015, 94(15):e680.
doi: 10.1097/MD.0000000000000680 |
[20] |
Li W, Chen Y, Sun ZP, et al. Clinicopathological characteristics of immunoglobulin G4-related sialadenitis[J]. Arthritis Res Ther, 2015, 17(1):186.
doi: 10.1186/s13075-015-0698-y |
[21] | 朱轩智, 张尽美, 吴亚菲, 等. 以牙龈增生为特征的IgG4相关性疾病1例[J]. 中华口腔医学杂志, 2022, 57(8):867-870. |
[22] |
Gontarz M, Wyszyńska-Pawelec G, Zapała J, et al. IgG4-related disease in the head and neck region:Report of two cases and review of the literature[J]. Pol J Pathol, 2016, 67(4):370-375.
doi: 29480 pmid: 28547965 |
[23] |
Zhang JM, Zhao L, Zhou JY, et al. Immunoglobulin G4-related periodontitis:Case report and review of the literature[J]. BMC Oral Health, 2021, 21(1):279.
doi: 10.1186/s12903-021-01592-2 |
[24] |
Cottom H, Mighell AJ, High A, et al. Are plasma cell-rich inflammatory conditions of the oral mucosa manifestations of IgG4-related disease?[J]. J Clin Pathol, 2015, 68(10):802-807.
doi: 10.1136/jclinpath-2014-202814 pmid: 26056156 |
[25] |
Bukhari AF, Magnuson BE, Desai B, et al. Diffuse palatal swelling[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(3):269-275.
doi: 10.1016/j.oooo.2019.12.003 |
[26] |
Laco J, Kamarádová K, Mottl R, et al. Plasma cell granuloma of the oral cavity—a mucosal manifestation of immunoglobulin G4-related disease or a mimic?[J]. Virchows Arch, 2015, 466(3):255-263.
doi: 10.1007/s00428-014-1711-6 |
[27] | Hashemi H, Thor A, Hellbacher E, et al. Localized IgG4-related disease manifested on the tongue:A case report[J]. Ups J Med Sci, 2021:126. |
[28] | Ali Khurram S, Fernando M, Smith AT, et al. IgG4-related sclerosing disease clinically mimicking oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e48-e51. |
[29] |
Andrew N, Kearney D, Sladden N, et al. Immunoglobulin G4-related disease of the hard palate[J]. J Oral Maxillofac Surg, 2014, 72(4):717-723.
doi: 10.1016/j.joms.2013.08.033 |
[30] | 张文, 董凌莉, 朱剑, 等. IgG 4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3):192-206. |
[31] |
Stone JH, Zen Y, Deshpande V. IgG4-related disease[J]. N Engl J Med, 2012, 366(6):539-551.
doi: 10.1056/NEJMra1104650 |
[32] |
Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(1):14-18.
doi: 10.1136/annrheumdis-2013-204907 pmid: 24651618 |
[33] | Ebbo M, Grados A, Bernit E, et al. Pathologies associated with serum IgG4 elevation[J]. Int J Rheumatol, 2012, 2012:602809. |
[34] |
Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis[J]. Curr Opin Rheumatol, 2011, 23(1):108-113.
doi: 10.1097/BOR.0b013e3283413469 pmid: 21124093 |
[35] |
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1):21-30.
doi: 10.1007/s10165-011-0571-z pmid: 22218969 |
[36] |
Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD[J]. Mod Rheumatol, 2021, 31(3):529-533.
doi: 10.1080/14397595.2020.1859710 |
[37] |
Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012, 25(9):1181-1192.
doi: 10.1038/modpathol.2012.72 |
[38] |
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7):1688-1699.
doi: 10.1002/art.v67.7 |
[39] |
Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1):1-6.
doi: S1424-3903(16)31250-9 pmid: 28027896 |
[40] |
Kawa S, Okazaki K, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis[J]. J Gastroenterol, 2014, 49(5):765-784.
doi: 10.1007/s00535-014-0944-0 pmid: 24664402 |
[41] | Sugimoto M, Takagi T, Suzuki R, et al. Efficacy of steroid pulse therapy for autoimmune pancreatitis type 1:A retrospective study[J]. PLoS One, 2015, 10(9):e0138604. |
[42] |
Wu QJ, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases:A preliminary randomized controlled trial[J]. Int J Rheum Dis, 2017, 20(5):639-646.
doi: 10.1111/apl.2017.20.issue-5 |
[43] |
Moriyama M, Tanaka A, Maehara T, et al. Clinical characteristics of Mikulicz’s disease as an IgG4-related disease[J]. Clin Oral Invest, 2013, 17(9):1995-2002.
doi: 10.1007/s00784-012-0905-z |
[44] |
Fei YY, Chen Y, Zhang PP, et al. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J]. Sci Rep, 2017, 7(1):6195.
doi: 10.1038/s41598-017-06520-5 pmid: 28733656 |
[45] |
Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2016, 138(3):825-838.
doi: S0091-6749(16)00198-6 pmid: 26971690 |
[46] |
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease:A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6):1171-1177.
doi: 10.1136/annrheumdis-2014-206605 pmid: 25667206 |
[47] | Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease:Data from a French nationwide study of thirty-three patients[J]. PLoS One, 2017, 12(9):e0183844. |
[48] |
Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease[J]. Eur J Intern Med, 2020, 74:92-98.
doi: S0953-6205(19)30467-4 pmid: 31901297 |
[49] |
Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(12):2236-2243.
doi: 10.1136/annrheumdis-2014-205799 pmid: 25143523 |
[50] |
Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease:Delayed treatment induces fibrosis progression[J]. Rheumatology (Oxford), 2013, 52(4):679-683.
doi: 10.1093/rheumatology/kes358 pmid: 23258649 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||